Skip to main content
. 2024 Jul 9;20(9):6133–6145. doi: 10.1002/alz.14091

TABLE 1.

Characteristics of study participants in the total sample and by dementia status.

Total sample All‐cause dementia
Characteristics a (n = 5704) No (n = 5402) Yes (n = 302) p‐value
Age (y), median (IQR) 70.0 (7.0) 70.0 (7.0) 76.0 (11.0) <0.001
Female sex, n (%) 3268 (57.3) 3059 (56.6) 209 (69.2) <0.001
Educational level, n (%) <0.001
Illiterate 2308 (40.5) 2104 (38.9) 204 (67.5)
Primary school 2398 (42.0) 2321 (43.0) 77 (25.5)
Middle school or above 998 (17.5) 977 (18.1) 21 (7.0)
Farmers, n (%) 4920 (88.3) 4663 (87.9) 257 (94.8) <0.001
Ever smoking, n (%) 2028 (35.6) 1957 (36.2) 71 (23.6) <0.001
Current alcohol drinking, n (%) 1650 (28.9) 1614 (29.9) 36 (12.0) <0.001
Physical inactivity, n (%) 1949 (35.1) 1853 (35.0) 96 (37.2) 0.519
APOE ε4 carriers, n (%) 876 (15.9) 826 (15.8) 50 (17.9) 0.414
Hypertension, n (%) 3807 (67.3) 3604 (67.2) 203 (67.9) 0.864
Hyperlipidemia, n (%) 1387 (24.3) 1298 (24.0) 89 (29.5) 0.038
Severe depression, n (%) 51 (1.0) 39 (0.8) 12 (7.0) <0.001
Heart disease, n (%) 1343 (23.5) 1254 (23.2) 89 (29.5) 0.015
Stroke, n (%) 899 (15.8) 794 (14.7) 105 (34.8) <0.001
Type 2 diabetes, n (%) 820 (14.4) 763 (14.1) 57 (18.9) 0.027
Visceral obesity, n (%) 1471 (25.8) 1374 (25.4) 97 (32.1) 0.012
CMM‐I b
No. of CMDs, n (%) <0.001
0 3308 (58.0) 3186 (59.0) 122 (40.4)
1 1802 (31.6) 1683 (31.2) 119 (39.4)
2 522 (9.2) 471 (8.7) 51 (16.9)
3 72 (1.3) 62 (1.1) 10 (3.3)
Presence of CMM, n (%) <0.001
No 5110 (89.6) 4869 (90.1) 241 (79.8)
Yes 594 (10.4) 533 (9.9) 61 (20.2)
CMM‐II c
No. of CMDs, n (%) <0.001
0 2581 (45.2) 2488 (46.1) 93 (30.8)
1 2019 (35.4) 1915 (35.4) 104 (34.4)
2 836 (14.7) 761 (14.1) 75 (24.8)
3 230 (4.0) 204 (3.8) 26 (8.6)
4 38 (0.7) 34 (0.6) 4 (1.3)
Presence of CMM, n (%) <0.001
No 4600 (80.6) 4403 (81.5) 197 (65.2)
Yes 1104 (19.4) 999 (18.5) 105 (34.8)
Plasma AD‐related biomarkers (n = 1439) n = 1439 n = 1299 n = 140
NfL (pg/mL), median (IQR) 12.5 (7.7) 12.0 (6.8) 18.7 (15.1) <0.001
Aβ42 (pg/mL), median (IQR) 11.9 (3.7) 11.8 (3.7) 12.6 (4.3) 0.020
Aβ40 (pg/mL), median (IQR) 169.0 (56.2) 168.0 (54.4) 188.0 (66) <0.001
Total tau (pg/mL), median (IQR) 2.3 (1.2) 2.3 (1.2) 2.7 (1.5) <0.001
Aβ42/Aβ40 ratio (×1000), median (IQR) 69.8 (19.5) 70.3 (19.5) 65.4 (18.2) 0.011
Serum cytokines (n = 1804) n = 1809 n = 1623 n = 186
IL‐6 (pg/mL), median (IQR) 0.9 (0.7) 0.9 (0.7) 1.0 (1.0) <0.001
IL‐8 (pg/mL), median (IQR) 18.1 (21.1) 18.1 (21.1) 18.6 (21.4) 0.836
TNF‐α (pg/mL), median (IQR) 1.6 (0.7) 1.6 (0.7) 1.8 (0.9) <0.001

Notes: Data are median (IQR) or n (%).

Abbreviations: Aβ, amyloid‐β; AD, Alzheimer's disease; APOE, apolipoprotein E; CMDs, cardiometabolic diseases; CMM, cardiometabolic multimorbidity; IL‐6, interleukin‐6; IL‐8, interleukin‐8; IQR, interquartile range; NfL, neurofilament light chain; TNF‐α, tumor necrosis factor‐α.

a

The number of participants with missing values was 130 for occupation, two for smoking, one for alcohol drinking, 158 for physical inactivity, 208 for APOE ε4 allele, 45 for hypertension, and 461 for severe depression. As a covariate in subsequent analyses, a dummy variable was created for each of the categorical variables to represent those with missing values.

b

CMM‐I was defined as the concurrent presence of two or more of the following three cardiometabolic diseases: type 2 diabetes, heart disease, and stroke.

c

CMM‐II was defined as the concurrent presence of two or more of the following four cardiometabolic diseases: visceral obesity, type 2 diabetes, heart disease, and stroke.